0001493152-21-015788.txt : 20210630 0001493152-21-015788.hdr.sgml : 20210630 20210630190117 ACCESSION NUMBER: 0001493152-21-015788 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210629 FILED AS OF DATE: 20210630 DATE AS OF CHANGE: 20210630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANDREWS DEBORAH J CENTRAL INDEX KEY: 0001325697 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 211063394 MAIL ADDRESS: STREET 1: 1911 WALKER AVE. CITY: MONROVIA STATE: CA ZIP: 91016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0306 4 2021-06-29 0 0000876343 Lineage Cell Therapeutics, Inc. LCTX 0001325697 ANDREWS DEBORAH J C/O LINEAGE CELL THERAPEUTICS 2173 SALK AVENUE, SUITE 200 CARLSBAD CA 92008 1 0 0 0 Common Shares, no par value 2021-06-29 4 M 0 24720 2.2 A 34720 D Common Shares, no par value 2021-06-29 4 S 0 19142 2.93 D 15578 D Stock Option (right to buy) 2.2 2021-06-29 4 M 0 24720 0 D 2021-06-30 Common Shares 24720 0 D The price reported is a weighted average. These shares were sold in multiple transactions at a price of $2.93 or $2.935. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016 Exhibit 24.1 - Substitute Power of Attorney /s/ Grant Harbert, as Attorney-in-Fact 2021-06-30 EX-24.1 2 ex24-1.htm

Exhibit 24.1

SUBSTITUTE POWER OF ATTORNEY

Under the terms of a power of attorney dated July 3, 2019 (the “Power of Attorney”), the undersigned, Chase C. Leavitt, was appointed attorney-in-fact for Deborah Andrews (the “Grantor”) to (1) prepare, execute in the Grantor’s name and on the Grantor’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the Grantor to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any rule or regulation of the SEC; (2) execute for and on behalf of the Grantor, in the Grantor’s capacity as an officer and/or director of Lineage Cell Therapeutics, Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder; (3) do and perform any and all acts for and on behalf of the Grantor which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interest of, or legally required by, the Grantor. In accordance with the authority granted under the Power of Attorney, including the full power of substitution, the undersigned hereby appoints each of Daniel W. Collins, Alexandra Hernandez, and Grant Harbert as substitute attorneys-in-fact, on behalf of the Grantor, each with the power to act without any other and with full power of substitution, to exercise and execute all of the powers granted or conferred in the original Power of Attorney. By their signatures as attorneys-in-fact to this Substitute Power of Attorney, Daniel W. Collins, Alexandra Hernandez, and Grant Harbert accept such appointment and agree to assume from the undersigned any and all duties and responsibilities attendant to their capacity as attorneys-in- fact.

Date: May 14, 2021	By:	/s/ Chase C. Leavitt
	Name:	Chase C. Leavitt
	Title:	Attorney-in-Fact

SUBSTITUTION AND APPOINTMENT ACCEPTED:
/s/ Daniel W. Collins
Daniel W. Collins

/s/ Alexandra Hernandez
Alexandra Hernandez

/s/ Grant Harbert
Grant Harbert